A Randomized, Active Therapy Controlled Phase 2 Study to Assess the Safety and Efficacy of ADXS11-001 with and without Cisplatin as 2nd Line Therapy for the Treatment of Recurrent Cervix Cancer.

Trial Profile

A Randomized, Active Therapy Controlled Phase 2 Study to Assess the Safety and Efficacy of ADXS11-001 with and without Cisplatin as 2nd Line Therapy for the Treatment of Recurrent Cervix Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Axalimogene filolisbac (Primary) ; Cisplatin
  • Indications Cervical cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Apr 2016 Results published in Advaxis media release.
    • 21 Jan 2014 Status changed from active, no longer recruiting to completed, according to an Advaxis media release.
    • 03 Sep 2013 Updated overall survival (18 months), tumour response and safety data will be presented at the 2013 Society for Immunotherapy of Cancer Annual Meeting according to an Advaxis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top